Literature DB >> 25456649

Insulin tactics in type 2 diabetes.

Farah Meah1, Rattan Juneja2.   

Abstract

Insulin is the most powerful glycemic control agent available. However, its use as a therapeutic modality requires education of the patient and regimentation of food intake, exercise, and frequent glucose monitoring. Such regimentation is particularly important when using a basal-bolus therapy approach. The introduction of many novel noninsulin drugs in the past decade has resulted in better glycemic control and often a need to reduce previously instituted insulin therapy. Although many of these novel therapies by themselves do not cause hypoglycemia, by reducing the overall glycemic burden through a myriad of mechanisms, they function in an insulin-sparing fashion. The doses of exogenously administered insulin may therefore need to be reduced in the presence of these new drugs to mitigate hypoglycemia. For insulin therapy (or any other drug treatment) to be successful, it is critical that the physician not only establish glycemic goals, but communicate these goals to the patient. The measurement of HbA1c helps in achieving a long-term goal, but on a day-today basis, patients need to be cognizant of their own BG goals and what they need to do if falling outside of target. The patients' understanding of self-management skills and empowerment are therefore foundational to insulin therapy.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Exogenous insulin profiles; Insulin adjustment; Insulin administration; Insulin secretion; Noninsulin therapy; Type 2 diabetes

Mesh:

Substances:

Year:  2014        PMID: 25456649     DOI: 10.1016/j.mcna.2014.08.021

Source DB:  PubMed          Journal:  Med Clin North Am        ISSN: 0025-7125            Impact factor:   5.456


  3 in total

Review 1.  How do I manage hyperglycemia/post-transplant diabetes mellitus after allogeneic HSCT.

Authors:  S Fuji; A Rovó; K Ohashi; M Griffith; H Einsele; M Kapp; M Mohty; N S Majhail; B G Engelhardt; A Tichelli; B N Savani
Journal:  Bone Marrow Transplant       Date:  2016-04-04       Impact factor: 5.483

2.  Resource use and outcomes associated with initiation of injectable therapies for patients with type 2 diabetes mellitus.

Authors:  Richard Brice; Sharon Shelley; Pankaj Chaturvedi; Divina Glah; Donna Ashley; Monica Hadi
Journal:  Drugs Context       Date:  2015-01-23

3.  Autophagy and its link to type II diabetes mellitus.

Authors:  Jai-Sing Yang; Chi-Cheng Lu; Sheng-Chu Kuo; Yuan-Man Hsu; Shih-Chang Tsai; Shih-Yin Chen; Yng-Tay Chen; Ying-Ju Lin; Yu-Chuen Huang; Chao-Jung Chen; Wei-De Lin; Wen-Lin Liao; Wei-Yong Lin; Yu-Huei Liu; Jinn-Chyuan Sheu; Fuu-Jen Tsai
Journal:  Biomedicine (Taipei)       Date:  2017-06-14
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.